|1.||Lietman, Thomas M: 34 articles (11/2015 - 02/2003)|
|2.||West, Sheila K: 30 articles (08/2015 - 04/2003)|
|3.||Gaynor, Bruce D: 25 articles (11/2015 - 11/2004)|
|4.||Munoz, Beatriz: 25 articles (10/2014 - 01/2003)|
|5.||Porco, Travis C: 22 articles (11/2015 - 01/2009)|
|6.||Keenan, Jeremy D: 20 articles (11/2015 - 01/2009)|
|7.||Mkocha, Harran: 20 articles (10/2014 - 01/2005)|
|8.||Zhou, Zhaoxia: 18 articles (09/2014 - 11/2004)|
|9.||Solomon, Anthony W: 17 articles (10/2015 - 04/2003)|
|10.||Emerson, Paul M: 17 articles (10/2015 - 03/2009)|
01/01/2011 - "it is known that the efficacy of azithromycin, in animal infection models, is best correlated with AUC/MIC. "
09/01/2003 - "These results suggest that azithromycin is effective in the prophylaxis and early infection of a highly virulent strain of T. "
11/01/1996 - "Although the clinical significance of antibiotic concentrations in these compartments is nuclear, the sustained lung tissue penetration and extensive phagocytic accumulation demonstrated in this study support the proven efficacy of azithromycin administered on a 5-day dosage schedule in the treatment of extracellular or intracellular pulmonary infections."
05/01/2005 - "In contrast, azithromycin was significantly more effective in eradicating persistent infection (MBC(100) = 2.5 to 5.0 microg/ml) than acute infection (MBC(100) = 10 to 50 microg/ml). "
01/01/2004 - "In conclusion, azithromycin was effective for reduction of respiratory symptoms in patients with chronic Cpn infection, but prolonged intermittent treatment with high doses did not eradicate the chronic infection."
03/01/2014 - "Mass oral azithromycin distributions have dramatically reduced the prevalence of the ocular strains of chlamydia that cause trachoma. "
11/01/2004 - "Azithromycin is highly effective against trachoma, but the practical difficulties of community-wide distribution often leave many individuals untreated. "
01/01/2012 - "Mass treatment with azithromycin to control trachoma can be considered cost effective in the African but not the South East Asian sub-region. "
01/01/2009 - "Repeated mass azithromycin distributions are effective in controlling the ocular strains of chlamydia that cause trachoma. "
01/01/2008 - "Analysis of associations between the A,F,E components of the SAFE strategy and active trachoma showed independent protective effects against active trachoma of mass systemic azithromycin treatment, facial cleanliness, face washing, and use of pit latrines in the household. "
|3.||Cystic Fibrosis (Mucoviscidosis)
04/01/2005 - "Azithromycin appears to be safe and effective, and is thus the most promising antiinflammatory therapy available for patients with cystic fibrosis. "
09/01/2009 - "Although long-term use of azithromycin has shown a significant clinical improvement for patients with cystic fibrosis (CF), its long-term effect on the susceptibility of commensal flora within CF airways has not yet been examined. "
11/01/2004 - "The evidence for the clinical benefit of azithromycin in cystic fibrosis has been summarized in a Cochrane review in which a meta-analysis confirmed a significant improvement in forced expiratory volume in 1 second among the 286 pooled participants. "
09/28/2002 - "The macrolide antibiotic azithromycin has anti-inflammatory properties potentially beneficial in cystic fibrosis. "
11/01/2007 - "Azithromycin has antiinflammatory properties and is effective in cystic fibrosis (CF) patients. "
|4.||Respiratory Tract Infections (Respiratory Tract Infection)
01/01/1992 - "The efficacy of azithromycin against lower respiratory tract infections has been proven in several clinical studies. "
10/01/1994 - "These results suggest that azithromycin may be useful in the treatment of respiratory infections caused by intracellular pathogens, including chlamydia because of its excellent accumulation within host cells."
01/01/2007 - "Efficacy of azithromycin administration in prevention of respiratory tract infection after bronchoscopic biopsy: a randomized, controlled trial."
09/01/1996 - "Azithromycin was given to 55 cases of lower respiratory tract infections in the doses of 500 mg on day 1, followed by 250 mg on days 2-5. It produced bacteriological cure in 70.8% patients and clinical cure or improvement in 69.09% of patients. "
09/01/1996 - "Evaluation of safety and efficacy of azithromycin in lower respiratory tract infections (LRTI)"
01/01/2003 - "Azithromycin proved to be effective cure for environmental pneumonia. "
09/01/2005 - "We evaluated the efficacy of azithromycin therapy given as a single high dose or divided over 5 days for the treatment of mild experimental Mycoplasma pneumoniae pneumonia. "
10/01/1991 - "Side effects were observed in one patient in Group I and in one patient in Group II. The results suggest that a 1.5 g total dose of azithromycin is equally effective when administered as a three- or five-day regimen for the treatment of atypical pneumonia."
03/01/1995 - "This study was designed to evaluate the efficacy of a 3 day course of azithromycin in low to moderately severe community-acquired pneumonia. "
06/01/2004 - "[Efficacy of azithromycin as the empiric therapy in children with community-acquired pneumonia who were isolated macrolide resistant Streptococcus pneumoniae from nasopharynx]."
|6.||Anti-Bacterial Agents (Antibiotics)
|1.||Transplantation (Transplant Recipients)